Characteristics, treatments and 1‐year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long‐Term Registry

摘要

Aims To describe the characteristics and assess the 1‐year outcomes of hospitalized (HHF) and chronic (CHF) heart failure patients with chronic obstructive pulmonary disease (COPD) enrolled in a large European registry between May 2011 and April 2013. Methods and results Overall, 1334/6920 (19.3%) HHF patients and 1322/9409 (14.1%) CHF patients were diagnosed with COPD. In both groups, patients with COPD were older, more frequently men, had a worse clinical presentation and a higher prevalence of co‐morbidities. In HHF, the increase in the use of heart failure (HF) medications at hospital discharge was greater in non‐COPD than in COPD for angiotensin‐converting enzyme inhibitors (+13.7% vs. +7.2%), beta‐blockers (+20.6% vs. +11.8%) and mineralocorticoid receptor antagonists (+20.9% vs. +17.3%), thus widening the gap in HF treatment already existing between the two groups at admission. In CHF patients, there was a similar increase in the use of these medications after enrollment visit in the two groups, leaving a significant difference of 8.2% for beta‐blockers in favour of non‐COPD patients (89.8% vs. 81.6%, P ??0.001). At 1‐year follow‐up, the hazard ratios for COPD in multivariable analysis confirmed its independent association with hospitalizations both in HHF [all‐cause: 1.16 (1.04–1.29), for HF: 1.22 (1.05–1.42)] and CHF patients [all‐cause: 1.26 (1.13–1.41), for HF: 1.37 (1.17–1.60)]. The association between COPD and all‐cause mortality was not confirmed in both groups after adjustments. Conclusions COPD frequently coexists in HHF and CHF, worsens the clinical course of the disease, and significantly impacts its therapeutic management and prognosis. The matter should deserve greater attention from the cardiology community.